POON Chiu Yee, Liona

POON Chiu Yee, Liona

Current Position:
Professor (Clinical)

Office Phone:
(852) 3505 2582

Email:
liona.poon@cuhk.edu.hk

 

Biographical details
Liona Poon was awarded MBBS from University of London in 2002 and undertook her specialty training in Obstetrics and Gynaecology in London. She gained a 3-year training fellowship from the Fetal Medicine Foundation and during this time, established a major screening programme for early detection of preeclampsia, which led to a Doctorate of Medicine (Research) in 2011. She then undertook subspecialty training in maternal fetal medicine at Imperial College Healthcare NHS Trust and King’s College Hospital NHS Foundation Trust with Mr TG Teoh and Professor KH Nicolaides as supervisors.

Qualifications:
MBBS (University of London), MRCOG, MD(Res) (University of London), Cert RCOG (Maternal and Fetal Medicine)

Research interests:
Her main research interests are in the prediction and prevention of maternal and perinatal morbidity and mortality. These include developing screening models for the prediction of aneuploidies, preeclampsia, fetal growth restriction, gestational diabetes, macrosomia, stillbirth, spontaneous preterm birth and induced labour. She is currently conducting a pan-European multicentre randomised controlled trial of Aspirin vs. placebo in the prevention of preterm preeclampsia (ASPRE), which is funded by the EC FP7 scheme. She has authored over 100 peer-reviewed publications in the top quartile of international journals in the field of Obstetrics and Gynaecology and Hypertension.

Grants:
EC FP7 (601852-2), NIHR EME (14/01/02), NIHR HTA (14/158), CUHK Start-up Support Fund, HK O&G Trust Fund

 

1Comment on "First Trimester screening for early and late preeclampsia based on maternal characteristics, biophysical parameters, and angiogenic factors"
Sahota DS, Poon LC
Prenat Diagn. 2018 Oct;38(11):891, 1 page
2Updates on Screening, Prevention, Treatment, and Genetic Markers for Preeclampsia
Palomaki GE, Martin JN Jr, Karumanchi SA, Poon LC
Clin Chem. 2018 Dec;64(12):1684-1689
3Objective assessment of the fetal facial profile at second and third trimester of pregnancy
Lu J, Sahota DS, Poon LC, Ting YH, Cheng YKY, Wang Y, Leung TY
Prenat Diagn. 2019 Jan;39(2):107-115
4The first-trimester of pregnancy - a window of opportunity for prediction and prevention of pregnancy complications and future life  
Poon LC, McIntyre HD, Hyett JA, da Fonseca EB, Hod M
Diabetes Res Clin Pract. 2018 Nov;145:20-30
5Maternal hemodynamics, fetal biometry and Doppler indices in pregnancies followed up for suspected fetal growth restriction
Roberts LA, Ling HZ, Poon LC, Nicolaides KH, Kametas NA
Ultrasound Obstet Gynecol. 2018 Oct;52(4):507-514
6Transverse technique: complementary approach to measurement of first-trimester uterine artery Doppler
Drouin O, Johnson J, Metcalfe A, Huber J, Schwarzenberger J,  Winters E, Stavness L, Chaemsaithong P, Tse AWT, Lu J, Lim WT, Leung TY, Bujold E, Sahota D, Poon LC
Ultrasound Obstet Gynecol. 2018 Nov;52(5):639-647
7Prediction of labor outcome using serial transperineal ultrasound in the first stage of labor
Chor CM, Poon LC, Leung TY
J Matern Fetal Neonatal Med. 2019 Jan;32(1):31-37
8Prediction and prevention of small-for-gestational-age neonates: evidence from SPREE and ASPRE
Tan MY, Poon LC, Rolnik DL, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Greco E, Papaioannou G, Wright D, Nicolaides KH
Ultrasound Obstet Gynecol. 2018 Jul;52(1):52-59
9Uterine artery pulsatility index in the first trimester: assessment of intersonographer and intersampling site measurement differences
Chaemsaithong P, Ting YH, Cheng KYY, Poon LC, Leung TY, Sahota DS
J Matern Fetal Neonatal Med. 2018 Sep;31(17):2276-2283
10ASPRE trial: incidence of preterm pre-eclampsia in patients fulfilling ACOG and NICE criteria according to risk by FMF algorithm
Poon LC, Rolnik DL, Tan MY, Delgado JL, Tsokaki T, Akolekar R, Singh M, Andrade W, Efeturk T, Jani JC, Plasencia W, Papaioannou G, Blazquez AR, Carbone IF, Wright D, Nicolaides KH
Ultrasound Obstet Gynecol. 2018 Jun;51(6):738-742
11Effect of change in posture on maternal functional hemodynamics at 35–37 weeks’ gestation
Guy GP, Ling HZ, Machuca M, Poon LC, Nicolaides KH
Ultrasound Obstet Gynecol. 2018 Mar;51(3):368-374
12Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia
Wright D, Poon LC, Rolnik DL, Syngelaki A, Delgado JL, Vojtassakova D, de Alvarado M, Kapeti E, Rehal A, Pazos A, Carbone IF, Dutemeyer V, Plasencia W, Papantoniou N, Nicolaides KH
Am J Obstet Gynecol. 2017 Dec;217(6):685.e1-685.e5
13Integrated Proteomic and Metabolomic prediction of Term Preeclampsia
Bahado-Singh R, Poon LC, Yilmaz A, Syngelaki A, Turkoglu O, Kumar P, Kirma J, Allos M, Accurti V, Li J, Zhao P, Graham SF, Cool DR, Nicolaides K
Sci Rep. 2017 Nov 23;7(1):16189 (Page 1-10)
14Impact of aspirin on trophoblastic invasion in women with abnormal uterine artery Doppler at 11-14 weeks: a randomized controlled study . E. Scazzocchio, D. Oros, D. Diaz, J. C. Ramirez, M. Ricart, E. Meler, R. González de Agüero, E. Gratacos and F. Figueras
Poon LC
Ultrasound Obstet Gynecol. 2017 Apr;49(4):433
15Protocol for measurement of mean arterial pressure at 10–40 weeks’ gestation
Roberts L, Chaemsaithong P, Sahota DS, Nicolaides KH, Poon LC
Pregnancy Hypertens. 2017 Oct;10:155-160
16Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history
Poon LC, Wright D, Rolnik DL, Syngelaki A, Delgado JL, Tsokaki T, Leipold G, Akolekar R, Shearing S, De Stefani L, Jani JC, Plasencia W, Evangelinakis N, Gonzalez-Vanegas O, Persico N, Nicolaides KH
Am J Obstet Gynecol. 2017 Nov;217(5):585.e1-585.e5
17ASPRE trial: performance of screening for preterm pre-eclampsia
Rolnik DL, Wright D, Poon LC, Syngelaki A, O'Gorman N, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tenenbaum-Gavish K, Nicolaides KH
Ultrasound Obstet Gynecol 2017 Oct;50(4):492-495
18Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE).
O'Gorman N, Wright D, Rolnik DL, Nicolaides KH, Poon LC
BMJ Open. 2016 Jun 28;6(6):e011801. doi: 10.1136/bmjopen-2016-011801.
19Protocol for the prospective validation study: 'Screening programme for pre-eclampsia' (SPREE)
Tan MY, Koutoulas L, Wright D, Nicolaides KH, Poon LC
Ultrasound Obstet Gynecol. 2017 Aug;50(2):175-179
20Metabolomic determination of pathogenesis of late-onset preeclampsia
Bahado-Singh RO, Syngelaki A, Mandal R, Graham SF, Akolekar R, Han B, Bjondahl TC, Dong E, Bauer S, Alpay-Savasan Z, Turkoglu O, Ogunyemi D, Poon LC, Wishart DS, Nicolaides KH
J Matern Fetal Neonatal Med. 2017 Mar;30(6):658-664
21Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia
Rolnik DL, Wright D, Poon LC, O'Gorman N, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tenenbaum-Gavish K, Meiri H, Gizurarson S, Maclagan K, Nicolaides KH
N Engl J Med. 2017 Aug 17;377(7):613-622
22Accuracy of competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11–13 weeks' gestation
O'Gorman N, Wright D, Poon LC, Rolnik DL, Syngelaki A, Wright A, Akolekar R, Cicero S, Janga D, Jani J, Molina F S, Paco Matallana C, Papantoniou N, Persico N, Plasencia W, Singh M, Nicolaides K H
Ultrasound Obstet Gynecol 2017 Jun;49(6):751-755
23Maternal cardiac function at 35-37 weeks' gestation: relationship with birth weight
Guy G.P., Ling H.Z., Machuca M., Poon LC, Nicolaides K.H.
Ultrasound Obstet Gynecol. 2017 Jan;49(1):67-72
24Maternal cardiac function at 35-37 weeks’ gestation: prediction of preeclampsia and gestational hypertension
Guy GP, Ling HZ, Garcia P, Poon LC, Nicolaides KH
Ultrasound in Obstetrics and Gynecology Jan 2017;49(1):61-66
25Maternal Cardiovascular Function at 35-37 Weeks' Gestation: Relation to Maternal Characteristics
Guy GP, Ling HZ, Garcia P, Poon LC, Nicolaides KH
Ultrasound in Obstetrics and Gynecology Jan 2017;49(1):39-45
26Birth weight in live births and stillbirths
Poon LC, Tan MY, Yerlikaya G, Syngelaki A, Nicolaides KH
Ultrasound Obstet Gynecol Nov 2016;48(5):602-606
27Metabolomic Determination of Pathogenesis of Late-onset Preeclampsia.
Bahado-Singh RO, Syngelaki A, Mandal R, Akolekar R, Han B, Bjondahl TC, Dong E, Bauer S, Alpay-Savasan Z, Graham S, Turkoglu O, Ogunyemi D, Poon LC, Wishart DS, Nicolaides KH.
Journal of Maternal Fetal and Neonatal Medicine 2016, J Matern Fetal Neonatal Med. 2016; 28: 1-7.
28Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE).
O'Gorman N, Wright D, Rolnik DL, Nicolaides KH, Poon LC.
BMJ Open 2016; 6:e011801. doi: 10.1136/bmjopen-2016-011801.
29Risk of preterm birth following treatment for cervical disease: Stakeholder meeting summary.
Sasieni P, Castanon A, Landy R, Kyrgiou M, Kitchener H, Quigley M, Poon LC, Shennan A, Paraskevaidis E, Hollingworth A, Soutter P, Freeman Wang T, Peebles D, Prendeville W, Patnick J.
British J Obstet Gynaecol 2015; doi: 10.1111/1471-0528.13839.
30Cervical Cerclage for Preterm Birth Prevention in Twin Gestations with Short Cervix: A Case-Control_ Study.
Houlihan C, Poon LC, Ciarlo M, Kim E, Guzman ER, Nicolaides KH.
Ultrasound Obstet Gynecol 2016, doi: 10.1002/uog.15918.
31Cervical pessary for prevention of preterm birth in singleton pregnancies with short cervical length: a multicentre, randomized controlled trial.
Nicolaides KH, Syngelaki A, Poon LC, Picciarelli G, Tul N, Zamprakou A, Skyfta E, Parra-Cordero M, Palma-Dias R, Rodriquez Calvo J.
New England Journal of Medicine 2016; 374:1044-52.
32Contingent Screening for Small by Weight for Gestational Age Neonates.
Frick AP, Nicolaides KH, Poon LC.
Pediatr Endocrinol Rev 2016;13:568-573.
33The use of ultrasound and other markers for early detection of preeclampsia.
O'Gorman N, Nicolaides KH, Poon LC.
Womens Health (Lond Engl) 2016;12:199-207.
34Clinical implementation of routine screening for fetal trisomies by the cell-free DNA test contingent on results from first-trimester combined test.
Gil MM, Revello R, Poon LC, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2016; 47:45-52.
35Prediction of large for gestational age neonates: Screening by maternal factors and biomarkers in the three trimesters of pregnancy.
Frick A, Syngelaki S, Zheng MM, Poon LC*, Nicolaides KH.
Ultrasound in Obstet Gynecol 2016;47:332-339.
36Current controversies in prenatal diagnosis 3: Is there still a Value in a Nuchal Translucency Screening Ultrasound in conjunction with Maternal Plasma Non-Invasive cell free DNA testing?’
Wilson RD, Poon LC, and Ghidini A.
Prenatal Diagnosis 2015; doi: 10.1002/pd.4719. [Epub ahead of print_]
37First trimester prediction of HELLP Syndrome.
Oliveira N, Poon LC, Nicolaides KH, Baschat AA.
Prenatal diagnosis 2016; 36:29-33.
38Clinical validation of the IONA® test for first-trimester detection of trisomy 21, 18 and 13.
Poon LC, Dumidrascu-Diris D, Francisco C, Fantasia I, Nicolaides KH.
Ultrasound Obstet Gynecol 2016; 47:184-187
39Cervical pessaries for prevention of preterm birth: a randomised controlled trial.
Nicolaides KH, Syngelaki A, Poon LC, De Paco C, Plasencia W, Molina F, Picciarelli G, Tul N, Celik E, Lau TK, Conturso R.
Am J Obstet Gynecol 2016, 214:3.e1-9
40The prediction of preterm birth in twin pregnancy: an individual patient level meta-analysis.
Kindinger LM, Poon LC, Cacciatore S, MacIntyre, Fox NS, Schuit E, Mol B, Liem S, Lim A, Hermans F, Serra V, Perales A, Darzi A, Bennett P, Nicolaides KH, Teoh TG.
British J Obstet Gynaecol 2016; 123:877-884.
41Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks’ gestation.
O’Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, Nicolaides KH.
Am J Obstet Gynecol 2015, pii: S0002-9378(15)00900-X. doi: 10.1016/j.ajog.2015.08.034. [Epub ahead of print_]
42Prediction of small for gestational age neonates: screening by biophysical and biochemical markers at 19-24 weeks.
Poon LC, Lesmes C, Gallo DM, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol. 2015 May 18. doi: 10.1002/uog.14904. [Epub ahead of print_]
43Poon L. Re: Prediction of early- and late-onset pregnancy-induced hypertension using placental volume on three-dimensional ultrasound and uterine artery Doppler.
T. Arakaki, J. Hasegawa, M. Nakamura, S. Hamada, M. Muramoto, H. Takita, K. Ichizuka and A. Sekizawa. Ultrasound Obstet Gynecol 2015; 45: 539-543.
Ultrasound Obstet Gynecol 2015;45:513.
44Prediction of small for gestational age neonates: Screening by maternal serum biochemical markers at 19-24 weeks.
Lesmes C, Gallo DM, Gonzalez R, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol. 2015 May 13. doi: 10.1002/uog.14899. [Epub ahead of print_]
45Prediction of small-for-gestational-age neonates: maternal biochemical markers at 30-34 weeks.
Bakalis S, Gallo DM, Mendez O, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 46: 208-215.
46Prediction of small-for-gestational-age neonates: screening by biophysical and biochemical markers at 30-34 weeks.
Bakalis S, Peeva G, Gonzalez R, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol. 2015 Mar 31. doi: 10.1002/uog.14863. [Epub ahead of print_]
47Prediction of small-for-gestational-age neonates: screening by placental growth factor and soluble fms-like tyrosine kinase-1 at 35-37 weeks.
Fadigas C, Peeva G, Mendez O, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 46: 191-197.
48Prediction of small for gestational age neonates: screening by uterine artery Doppler and mean arterial pressure at 19-24 weeks.
Lesmes C, Gallo DM, Saiid Y, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol. 2015 Mar 24. doi: 10.1002/uog.14855. [Epub ahead of print_]
49Prediction of small-for-gestational-age neonates: screening by uterine artery Doppler and mean arterial pressure at 35-37 weeks.
Fadigas C, Guerra L, Garcia-Tizon Larroca S, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 45: 715-721.
50Umbilical and fetal middle cerebral artery Doppler at 35-37 weeks' gestation in the prediction of adverse perinatal outcome.
Akolekar R, Syngelaki A, Gallo DM, Poon LC, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 46: 82-92.
51Prediction of small-for-gestational-age neonates: screening by fetal biometry at 35-37 weeks.
Fadigas C, Saiid Y, Gonzalez R, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 45: 559-565.
52Competing risks model in screening for preeclampsia by maternal characteristics and medical history.
Wright D, Syngelaki A, Akolekar R, Poon LC, Nicolaides KH.
Am J Obstet Gynecol 2015; 213: 62.e1-62.e10.
53Prediction of small for gestational age neonates: screening by fetal biometry at 19-24 weeks.
Lesmes C, Gallo D, Panaiotova J, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 46: 198-207.
54Umbilical and fetal middle cerebral artery Doppler at 30-34 weeks' gestation in the prediction of adverse perinatal outcome.
Bakalis S, Akolekar R, Gallo DM, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 45: 409-420.
55Prediction of small for gestational age neonates: Screening by uterine artery Doppler and mean arterial pressure at 30-34 weeks.
Bakalis S, Stoilov B, Akolekar R, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 45: 707-714.
56Mean arterial pressure in the three trimesters of pregnancy: effects of maternal characteristics and medical history.
Wright A, Wright D, Ispas CA, Poon LC, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 45: 698-706.
57Prediction of small for gestational age neonates: screening by fetal biometry at 30-34 weeks.
Bakalis S, Silva M, Akolekar R, Poon LC*, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 45: 551-558.
58UK NHS pilot study on cell-free DNA testing in screening for fetal trisomies: Factors affecting uptake.
Gil MM, Giunta G, Macalli EA, Poon LC, Nicolaides KH.
Ultrasound Obstet Gynecol 2015; 45: 67-73.
59Fetal fraction in maternal plasma cell-free DNA in the prediction of spontaneous preterm delivery.
Quezada MS, Francisco C, Dumitrascu-Biris D, Nicolaides KH, Poon LC*.
Ultrasound Obstet Gynecol 2015; 45: 101-105.
60Maternal plasma cell-free DNA in the prediction of preeclampsia.
Rolnik DL, O’Gorman N, Fiolna M, van den Boom D, Nicolaides KH, Poon LC*.
Ultrasound Obstet Gynecol 2015; 45: 106-111.
61Early prediction of preeclampsia.
Poon LC, Nicolaides KH.
Obstet Gynecol Int. 2014; 2014: 297397.
62Management of hypertriglyceridaemia-induced acute pancreatitis in pregnancy.
Amin T, Poon L, Teoh T, Moorthy K, Robinson S.
J Matern Fetal Neonatal Med. 2014 Jul 29:1-13. [Epub ahead of print_]
63Maternal serum anti-Müllerian hormone at 11-13 weeks' gestation in the prediction of preeclampsia.
Birdir C, Fryze J, Vasiliadis H, Nicolaides KH, Poon LC*.
J Matern Fetal Neonatal Med 2015; 28: 954-958.
64Competing risk model in screening for preeclampsia by mean arterial pressure and uterine artery pulsatility index at 30-33 weeks' gestation.
Tayyar A, Garcia-Tizon Larroca S, Poon LC, Wright D, Nicolaides KH.
Fetal Diagn Ther. 2014; 36: 18-27.
65Demographic factors that can be used to predict early-onset pre-eclampsia.
Leung C, Saaid R, Pedersen L, Park F, Poon L, Hyett J.
J Matern Fetal Neonatal Med 2015; 28: 535-539.
66First-trimester maternal factors and biomarker screening for preeclampsia.
Poon LC, Nicolaides KH.
Prenat Diagn 2014; 34: 618-627.
67Successful induction of labor: prediction by pre-induction cervical length, angle of progression and cervical elastography.
Pereira S, Frick AP, Poon LC, Zamprakou A, Nicolaides KH.
Ultrasound Obstet Gynecol 2014; 44: 468-475.
68Is High Fetal Nuchal Translucency Associated with Submicroscopic Chromosomal Abnormalities by Array CGH?
Huang J, Poon LC, Akolekar R, Choy KW, Leung TY, Nicolaides KH.
Ultrasound Obstet Gynecol 2014; 43: 620-624.
69Competing risks model in screening for preeclampsia by biophysical and biochemical markers at 30-33 weeks’ gestation.
Garcia-Tizon Larroca S, Tayyar A, Poon LC, Wright D, Nicolaides KH.
Fetal Diagn Ther 2014; 36: 9-17.
70Prediction of preeclampsia by mean arterial pressure at 11-13 and 20-24 weeks’ gestation.
Gallo D, Poon LC, Fernandez M, Wright D, Nicolaides KH.
Fetal Diagn Ther 2014; 36: 28-37.
71Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks’ gestation.
Lai J, Garcia-Tizon Larroca S, Peeva G, Poon LC, Wright D, Nicolaides KH.
Fetal Diagn Ther 2014; 35: 240-248.
72Optimal method and timing of intrauterine intervention in TRAP sequence: case study and meta-analysis.
Chaveeva P, Poon LC, Sotiriadis A, Kosinski P, Nicolaides KH.
Fetal Diagn Ther 2014; 35: 267-279.
73Maternal serum placental growth factor (PlGF) isoforms 1 and 2 at 11-13, 20-24 and 30-34 weeks’ gestation in late onset preeclampsia and small for gestational age.
Nucci M, Poon LC, Demirdjian G, Darbouret B, Nicolaides KH.
Fetal Diagn Ther 2014; 35: 249-257.
74Nucci M, Poon LC, Demirdjian G, Darbouret B, Nicolaides KH.
Maternal serum placental growth factor (PlGF) isoforms 1 and 2 at 11-13 weeks’ gestation in preeclampsia and small for gestational age.
Fetal Diagn Therr 2014; 35: 249-257.
75Prediction of preeclampsia by uterine artery Doppler at 20-24 weeks’ gestation.
Gallo D, Poon LC, Akolekar R, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2013; 1: 241-247.
76Trichorionic and dichorionic triplet pregnancies at 10-14 weeks: Outcome after embryo reduction compared to expectant management.
Chaveeva P, Kosinski P, Puglia D, Poon L, Nicolaides K.
Fetal Diagn Ther 2013; 1: 199-205.
77First-trimester contingent screening for trisomies 21, 18 and 13 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Syngelaki A, Poon LC, Gil M, Wright D.
Fetal Diagn Ther 2014; 35: 185-192.
78Clinical evaluation of a first trimester algorithm predicting the risk of hypertensive disease of pregnancy.
Park FJ, Leung CH, Poon LC, Williams PF, Rothwell SJ, Hyett JA.
Aust N Z J Obstet Gynaecol 2013; 53: 532-539.
79How feasible is expectant management of interstitial ectopic pregnancy?
Poon LC, Emmanuel E, Ross J, Johns J.
Ultrasound Obstet Gynecol 2013, Ultrasound Obstet Gynecol 2014; 43: 317-321.
80Association of placental perfusion, as assessed by magnetic resonance imaging and uterine artery Doppler ultrasound, and its relationship to pregnancy outcome.
Derwig I, Lythgoe DJ, Barker GJ, Poon L, Gowland P, Yeung R, Fernando Z, Nicolaides, KH.
Placenta 2013; 34: 885-891.
81First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell free DNA testing.
Nicolaides KH, Wright D, Poon L, Syngelaki A, Gil M.
Ultrasound Obstet Gynecol 2013; 42: 41-50.
82Second-trimester screening for trisomy 21 using prefrontal space ratio.
Chaveeva P, Agathokleous M, Poon LC, Markova D, Nicolaides KH.
Fetal Diagn Ther 2013; 34: 50-55.
83Maternal thyroid function at 11-13 weeks’ gestation in twin pregnancy.
Ashoor G, Muto O, Poon LC, Abdulla M, Nicolaides KH.
Thyroid 2013; 23: 1165-1171.
84Maternal serum cytokines at 30-33 weeks in the prediction of preeclampsia.
Mosimann B, Wagner M, Poon LC, Bansal AS, Nicolaides KH.
Prenatal Diagnosis 2013; 33: 823-830.
85Association of placental T2 relaxation times and uterine artery Doppler ultrasound measures of placental blood flow.
Derwig I, Barker GJ, Poon L, Zelaya F, Gowland P, Lythgoe DJ, Nicolaides KH.
Placenta 2013; 34: 474-479.
86Natural killer cells and their activation status in normal pregnancy.
Mosimann B, Wagner M, Shehata H, Poon LC, Ford B, Nicolaides KH, Bansal AS.
International Journal of Reproductive Medicine 2013; 2013: 906813.
87Maternal plasma cell-free fetal and maternal DNA at 11-13 weeks’ gestation: Relation to fetal and maternal characteristics and pregnancy outcomes.
Poon LC, Musci T, Song K, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2013; 33: 215-223.
88Maternal Serum Placental Growth Factor, Pregnancy-Associated Plasma Protein-A and Free β-Human Chorionic Gonadotrophin at 30-33 Weeks in the Prediction of Pre-Eclampsia.
Lai J, Pinas A, Poon LC, Agathokleous M, Nicolaides KH.
Fetal Diagn Ther 2013; 33: 164-172.
89Meta-analysis of second-trimester markers for trisomy 21.
Agathokleous M, Chaveeva P, Poon LC, Kosinski P, Nicolaides KH.
Ultrasound Obstet Gynecol 2013; 41: 247-261.
90Maternal serum tumour necrosis factor receptor 1 (TNF-R1) at 30-33 weeks in the prediction of preeclampsia.
Mosimann B, Wagner M, Birdir C, Poon LC, Nicolaides KH.
J Matern Fetal Neonatal Med 2013; 26: 763-767.
91Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation: relation to maternal and fetal characteristics.
Ashoor G, Syngelaki A, Poon L, Rezende J, Nicolaides K.
Ultrasound Obstet Gynecol 2013; 41: 26-32.
92Maternal serum retinol-binding protein-4 at 11-13 weeks’ gestation in normal and pathological pregnancies.
Nanda S, Nikoletakis G, Markova D, Poon LC, Nicolaides KH.
Metabolism 2013; 62: 814-819.
93Maternal serum activin-A at 30-33 weeks in the prediction of preeclampsia.
Lai J, Pinas A, Syngelaki A, Poon LC, Nicolaides KH.
J Matern Fetal Neonatal Med 2013; 26: 733-737.
94Mean arterial pressure, systolic and diastolic blood pressure at 30–33 weeks in the prediction of preeclampsia.
Lai J, Poon LC, Bakalis S, Markova D, Nicolaides KH.
Fetal Diagn Ther 2013; 33: 173-181.
95Uterine artery Doppler at 30–33 weeks’ gestation in the prediction of preeclampsia.
Lai J, Poon LC, Pinas A, Bakalis S, Nicolaides KH.
Fetal Diagn Ther 2013; 33: 156-163.
96Second-trimester uterine artery Doppler in the prediction of stillbirths.
Poon LC, Volpe N, Muto B, Yu CKH, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2013; 33: 28-35.
97Combined screening for preeclampsia and small for gestational age at 11–13 weeks.
Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH.
Fetal Diagn Ther 2013; 33: 16-27.
98Competing risks model in early screening for preeclampsia by biophysical and biochemical markers.
Akolekar R, Syngelaki A, Poon LC, Wright D, Nicolaides KH.
Fetal Diagn Ther 2013; 33: 8-15.
99Maternal serum soluble endoglin (sEng) at 30-33 weeks in the prediction of preeclampsia.
Lai J, Syngelaki A, Poon LC, Nucci M, Nicolaides KH.
Fetal Diagn Ther 2013; 33: 149-155.
100A competing risks model in early screening for preeclampsia.
Wright D, Akolekar R, Syngelaki A, Poon LC, Nicolaides KH.
Fetal Diagn Ther 2012; 32: 171-178.
101Birthweight with gestation and maternal characteristics in live births and stillbirths.
Poon LC, Volpe N, Muto B, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2012; 32: 156-165.
102C-reactive protein at 11 to 13 weeks’ gestation in spontaneous early preterm delivery.
Bakalis S, Poon LC, Vayna AM, Pafilis I, Nicolaides KH.
J Matern Fetal Neonatal Med 2012; 25: 2475-2478.
103Maternal serum ferritin at 11 to 13 weeks’ gestation in spontaneous early preterm delivery.
Beta J, Poon LC, Bakalis S, Mosimann B, Nicolaides KH.
J Matern Fetal Neonatal Med 2012; 25:1852-1855.
104Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks’ gestation: Effect of maternal and fetal factors.
Ashoor G, Poon LC, Syngelaki A, Mosimann B, Nicolaides KH.
Fetal Diagn Ther 2012; 31: 237-243.
105First trimester screening for spontaneous preterm delivery with maternal characteristics and cervical length.
Greco E, Gupta R, Syngelaki A, Poon LC, Nicolaides KH.
Fetal Diagn Ther 2012; 31: 154-161.
106Protocol for measurement of mean arterial pressure at 11-13 weeks’ gestation.
Poon LC, Zymeri NA, Zamprakou A, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2012; 31: 42-48.
107First trimester screening for neural tube defects using AFP.
Bredaki FE, Poon LC, Birdir C, Escalante D, Nicolaides KH.
Fetal Diagn Ther 2012; 31: 109-114.
108Maternal serum resistin at 11-13 weeks’ gestation in normal and pathological pregnancies.
Nanda S, Poon LC, Muhaisen M, Acosta IC, Nicolaides KH.
Metabolism 2012; 61: 699-705.
109Large loop excision of transformation zone and cervical length in the prediction of spontaneous preterm delivery.
Poon LC, Savvas M, Zamblera D, Skyfta E, Nicolaides KH.
BJOG 2012; 119: 692-698.
110Systolic diastolic and mean arterial pressure at 11-13 weeks in the prediction of hypertensive disorders in pregnancy: a prospective screening study.
Poon LC, Kametas NA, Valencia C, Chelemen T, Nicolaides KH.
Hypertens Pregnancy 2011; 30: 93-107.
111First-trimester prediction of macrosomia.
Poon LC, Karagiannis G, Stratieva V, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2011; 29: 139-147.
112Reference range of birth weight with gestation and first-trimester prediction of small for gestation neonates.
Poon LC, Karagiannis G, Staboulidou I, Shafiei A, Nicolaides KH.
Prenat Diagn 2011; 31: 58-65.
113Normal ranges of embryonic length, embryonic heart rate, gestational sac diameter and yolk sac diameter in early pregnancy.
Papaioannou GKI, Syngelaki A, Poon LC, Ross J, Nicolaides KH.
Fetal Diagn Ther 2010; 28: 207-219.
114Hypertensive disorders in pregnancy: Screening by biophysical and biochemical markers at 11-13 weeks.
Poon LC, Akolekar R, Lachmann R, Beta J, Nicolaides KH.
Ultrasound in Obstetrics and Gynecology 2010; 35: 662-670.
115Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11-13 weeks.
Poon LC, Stratieva V, Piras S, Piri S, Nicolaides KH.
Prenat Diagn 2010; 30: 216-223.
116Hypertensive disorders in pregnancy: Screening by uterine artery Doppler and blood pressure at 11-13 weeks.
Poon LC, Karagiannis G, Leal A, Romero Infante X, Nicolaides KH.
Ultrasound in Obstetrics and Gynecology 2009; 34: 497-502.
117Hypertensive disorders in pregnancy: Screening by uterine artery Doppler at 11-13 weeks.
Poon LC, Staboulidou I, Maiz N, Plasencia W, Nicolaides KH.
Ultrasound in Obstetrics and Gynecology 2009; 34: 142-148.
118Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach.
Poon LC, Kametas NA, Chelemen T, Leal A, Nicolaides KH.
J Hum Hypertens 2010; 24: 104-110.
119First-trimester prediction of hypertensive disorders in pregnancy.
Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH.
Hypertension 2009; 53: 812-818.
120First-trimester maternal serum matrix metalloproteinase-9 (MMP-9) and adverse pregnancy outcome.
Poon LC, Nekrasova E, Anastassopoulos P, Livanos P, Nicolaides KH.
Prenatal Diagnosis 2009; 29: 553-559.
121Maternal serum placental growth factor (plgf) at 11+0 to 13+6 weeks of gestation in small for gestational age pregnancy.
Poon LC, Zaragoza E, Akolekar R, Anagnostopoulos E, Nicolaides KH.
Prenatal Diagnosis 2008; 28: 1110-1115.
122First trimester urinary placental growth factor and development of pre-eclampsia.
Savvidou M, Akolekar R, Zaragoza E, Poon L, Nicolaides KH.
BJOG 2009; 116: 643-647.
123First-trimester maternal serum tumor necrosis factor receptor-1 (TNF-R1) and preeclampsia.
Leal AM, Poon LC, Frisova V, Veduta A, Nicolaides KH.
Ultrasound in Obstetrics and Gynecology 2009; 33: 135-141.
124Maternal serum placental growth factor (plgf) at 11+0 to 13+6 weeks of gestation in hypertensive disorders of pregnancy.
Akolekar R, Zaragoza E, Poon LC, Pepes S, Nicolaides KH.
Ultrasound in Obstetrics and Gynecology 2008; 32: 732-739.
125Maternal serum placental growth factor (plgf) at 11+0-13+6 weeks in chromosomally abnormal pregnancies.
Zaragoza E, Akolekar R, Poon LC, Pepes S, Nicolaides KH.
Ultrasound in Obstetrics and Gynecology 2009; 33: 382-386.
126First-trimester maternal serum PAPP-A and preeclampsia.
Poon LC, Maiz N, Valencia C, Plasencia W, Nicolaides KH.
Ultrasound in Obstetrics and Gynecology 2009; 33: 23-33.
127Maternal serum ADAM12 (A Disintegrin And Metalloprotease) in chromosomally abnormal pregnancies at 11+0-13+6 weeks.
Poon LC, Chelemen T, Minekawa R, Frisova V, Nicolaides KH.
American Journal Obstetrics and Gynecology 2009; 200: 508.e1-6.
128First trimester maternal serum A Disintegrin And Metalloprotease 12 and adverse pregnancy outcome.
Poon LC, Chelemen T, Granvillano O, Pandeva I, Nicolaides KH.
Obstetric Gynecol 2008; 112: 1082-1090.
129Fetal Medicine Foundation Prolonged Pregnancy Group. Cervical length and maternal factors in expectantly managed prolonged pregnancy: prediction of onset of labor and mode of delivery.
Rao A, Celik E, Poggi S, Poon L, Nicolaides KH;
Ultrasound Obstet Gynecol 2008; 32: 646-651.
130Prediction of preeclampsia by a combination of maternal history, uterine artery doppler and mean arterial pressure.
Onwudiwe N, Yu CKH, Poon LC, Spiliopoulos I, Nicolaides KH.
Ultrasound Obstet Gynecol 2008; 32: 877-883.
131Uterine artery Doppler at 11+0-13+6 weeks and 21+0-24+6 weeks in the prediction of pre-eclampsia.
Plasencia W, Maiz N, Poon L, Yu C, Nicolaides KH.
Ultrasound Obstet Gynecol 2008; 32: 138-146.
132Inter-arm blood pressure differences in pregnant women.
Poon LC, Kametas N, Strobl I, Pachoumi C, Nicolaides KH.
BJOG 2008; 115: 1122-1130.
133Mean arterial pressure at 11+0-13+6 weeks in the prediction of pre-eclampsia.
Poon LC, Kametas N, Pandeva IV, Valencia CM, Nicolaides KH.
Hypertension 2008; 51: 1027-1033.
134Urine albumin concentration and albumin-to-creatinine ratio at 11+0-13+6 weeks in the prediction of pre-eclampsia.
Poon LC, Kametas N, Bonino S, Vercellotti E, Nicolaides KH.
BJOG 2008; 115: 866-873.
135Blood pressure levels correlate with intra-individual variability using an automated device in early pregnancy.
Poon LC, Kametas N, Valencia CM, Pandeva IV, Nicolaides KH.
J Hum Hypertens 2008; 22: 438-440.
136Tetralogy of Fallot in the fetus in the current era.
Poon LC, Huggon I, Zidere V and Allan LD.
Ultrasound Obstet Gynecol 2007; 29: 625-627.
137Audit of the effectiveness of cervical preparation with Dilapan prior to late second trimester (20-24 weeks) surgical termination of pregnancy.
Poon LC, Parsons J.
BJOG 2007; 114: 485-488.